Vascular Dysfunction in Diabetes: Genes and Hormones
NCT01511042 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2022-11-09
Summary
The investigators are very excited that the National Institutes of Health are sponsoring us to investigate why patients with diabetes are more likely to develop high blood pressure, atherosclerosis (hardening of the arteries), and heart disease. There are two parts of our research program. The first part is a screening visit. At this visit you will be given a brief physical exam and will be asked questions concerning your medical history. During the same visit you will have your blood drawn for routine screening and to prepare DNA for genetic testing. You will also be asked to collect a urine sample for routine screening.
If the doctor finds that you are a healthy candidate you will be invited to participate in the second part of the study. During Phase II the investigators will perform physiologic tests after you are placed on a low salt diet and again after you are placed on a high salt diet. All of the food that you will eat during the two diets will be provided to you by the hospital. If you are on blood pressure medication, it may be necessary to discontinue taking your present medication for up to three months before beginning the study. Patients discontinuing their current blood pressure medication may be placed on a different blood pressure medication during this washout period if necessary to maintain blood pressure at pre-study levels. The investigators will take you off all medications, except cholesterol medications two weeks prior to your scheduled in-patient study. However, if you are currently on medication to control your diabetes you will remain on this throughout the entire study.
Once your blood pressure medications are discontinued, you will be closely monitored to make sure you do not encounter any difficulty. If you do not own a home blood pressure monitor, the investigators will provide one for to use during the study so that you can keep a daily record of your blood pressure readings. The investigators will ask you to call us every three days to report your blood pressure readings. Less than 20% of patients with hypertension have any significant increase in their blood pressure during this short time off therapy. After you have been off your medication for nine days the dieticians will give you low salt meals to eat at home for six days. On the sixth day of the low salt diet, you will be asked to begin a 24-hour urine collection. You will also be required to come to the Ambulatory Clinical Center (221 Longwood Ave.) for a one-hour test. You will return that evening to the inpatient Clinical Research Center where you will be admitted for your first study that will occur the next morning. On the morning of your low salt study you will have three naturally occurring hormones administered and blood samples drawn from an intravenous needle. The investigators will also take ultrasound pictures of your heart to see how salt and hormones affect the way the heart functions. These tests will last approximately five hours and you will be discharged around 12:00 p.m. The dieticians will then give you your meals for the next week to take home. Each of these meals will have a high salt content. After six days of your high salt diet, on the morning of your second admission to the hospital, you will be asked to begin a final 24-hour urine collection. The same study that was done for the low salt study will be repeated for the high salt study. You will be discharged around 3:00 p.m. This study will determine if you are salt-sensitive. A high salt diet has been found to lead to higher blood pressure and weight gain. In addition, the investigators hope to learn more about the hormones that regulate your blood pressure and the genes responsible for regulating those hormones.
You will be placed back on your initial blood pressure medication (if you are on any) and returned to your regular physician for care. The investigators will provide clinically relevant information to you and your physician.
Conditions
Interventions
- DRUG
-
Para-aminohippuric Acid
Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated "PAH".
- DRUG
-
Angiotensin II
Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
- DRUG
-
Norepinephrine
A hormone that is normally present in your body, which regulates your blood pressure.
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Gordon H Williams, MD · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-12-31
- Primary Completion
- 2020-01-31
- Completion
- 2020-06-30
Countries
- United States
Study Locations
More Related Trials
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
NCT00762671 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus
NCT05806502 ·Status: COMPLETED ·Phase: NA
-
Resistant Hypertension in Patients With Type-II-Diabetes Mellitus
NCT01056367 ·Status: COMPLETED
-
Precise Treatment of Prediabetes and Stage 1 Hypertension
NCT04529590 ·Status: COMPLETED
-
Carotid Body Function in Type 2 Diabetes Mellitus
NCT05237076 ·Status: COMPLETED ·Phase: NA
-
Non-Traditional Cardiovascular Risk Factors in Type 2 Diabetes Mellitus - Ancillary to VA Study of Glycemic Control
NCT00021944 ·Status: COMPLETED
-
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
NCT05219994 ·Status: COMPLETED ·Phase: NA
-
Personalized Medicine for Diabetes Prediction and Prevention of Complications
NCT01268813 ·Status: UNKNOWN ·Phase: PHASE1
-
Risk Prediction in Type II Diabetics With Ischemic Heart Disease
NCT01422057 ·Status: UNKNOWN
-
Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus
NCT07237685 ·Status: RECRUITING
-
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
NCT06843304 ·Status: RECRUITING
-
Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk
NCT00520962 ·Status: COMPLETED
-
Mechanisms and Reversibility of Heart Failure Associated With Diabetes
NCT01970319 ·Status: COMPLETED
-
Phenotyping Individuals With Neo-diagnosed Type 2 Diabetes at Risk for All-cause Mortality
NCT04453605 ·Status: COMPLETED
-
Nutritional Therapy for Diabetic Cardiomyopathy
NCT01373814 ·Status: COMPLETED
-
Cohort Study in Type 2 Diabetes in China
NCT01076023 ·Status: UNKNOWN
-
Diabetes, Lipoproteins and Accelerated Vascular Disease
NCT00005479 ·Status: COMPLETED
-
Mechanisms of Endothelial Dysfunction in Type 2 Diabetes
NCT02311075 ·Status: COMPLETED ·Phase: NA
-
Carotid Atherosclerosis and Vascular Events in People With Diabetes
NCT02929355 ·Status: COMPLETED
-
A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias
NCT04660630 ·Status: UNKNOWN ·Phase: NA
-
Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications
NCT07250607 ·Status: ACTIVE_NOT_RECRUITING
-
An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes
NCT03786406 ·Status: COMPLETED
-
Morbidity in Newly Diagnosed type2 Diabetes in Adults
NCT02002091 ·Status: COMPLETED
-
Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects
NCT02109835 ·Status: UNKNOWN
-
Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1
NCT00574665 ·Status: COMPLETED ·Phase: NA